Antiviral activities of de novo designed peptides.

Peptide	Amino acid sequence	# of AA	S-S bond	HIV-1IIIB in CEM-SS cells			HSV-2MS in Vero cells
Peptide	Amino acid sequence	# of AA	S-S bond	EC50a (mg/ml)	TC50 (mg/ml)	TI	EC50 (mg/ml)	TC50 (mg/ml)	TI
BMAP-18	GRFKRFRKK FKKLFKKIS	18		0.83	19.8	23.9	27.2	>100	>3.7
SB1	GSKKPVPIIYC NRRTGKCQRI	21	C11-C18	13.1	>100	>7.6	64.9	>100	>1.5
SB2	GSRRPVPIIYC NRRTGRCQRI	21	C11-C18	3.33	>100	>30	>100	>100	---
GLK-19	GLKKLLGKLL KKLGKLLLK	19		>47.5	25.1	<0.5	n.e.b	n.e.
GLR-19	GLRRLLGRLL RRLGRLLLR	19		4.06	17.8	4.4	2.32	12.4	5.3
GLRC-1	GCRRLLGRLLRRLGRLLCR	19	C2-C18	>100	59.2	<1.0	30	>100	>3.3
GLRC-2	GLRCRLGRLLRRLGRCLLR	19	C4-C16	1.81	17.8	9.83	5.43	31.8	5.9
GLRC-3	GLRRLCGRLGRRLCRLLLR	19	C6-C14	6.37	18.5	2.9	15	62.3	4.2
GLRC-4	GCRRLCGRLGRRLCRLLCR	19	C2-C18 C6-C14	69.3	>100	>1.44	64.7	>100	>1.5
GLRC-5	GLRCRLGRLLRRLGRC	16	C4-C16	>100	59.5	<1.00	n.e.	n.e.
GLRC-6	CRLGRLLRRLGRCLLR	16	C1-C13	7.72	41.9	5.43	n.e.	n.e.
GLRC-7	CRLGRLLRRLGRC	13	C1-C13	>100	>100	---	n.e.	n.e.
GLRC-8	GLRCLRLRGRLRLGRCLLR	19	C4-C16	>100	31	<1.00	n.e.	n.e.

Table 1: Antiviral activities of de novo designed peptides. aAlthough not provided in the table, the standard error from multiple antiviral assays is on average less than 10% of the respective mean EC50 or TC50 values. bn.e., not evaluated.

Goto home»